Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

被引：70

作者：

Cantini, Fabrizio ^{[1
]}

Niccoli, Laura ^{[1
]}

Nannini, Carlotta ^{[1
]}

Matarrese, Daniela ^{[2
]}

Di Natale, Massimo Edoardo ^{[3
]}

Lotti, Pamela ^{[3
]}

Aquilini, Donatella ^{[4
]}

Landini, Giancarlo ^{[5
]}

Cimolato, Barbara ^{[5
]}

Di Pietro, Massimo Antonio ^{[6
]}

Trezzi, Michele ^{[6
]}

Stobbione, Paolo ^{[7
]}

Frausini, Gabriele ^{[8
]}

Navarra, Assunta ^{[9
]}

Nicastri, Emanuele ^{[10
]}

Sotgiu, Giovanni ^{[11
]}

Goletti, Delia ^{[12
]}

机构：

[1] Hosp Prato, Azienda USL Toscana Ctr, Dept Rheumatol, Prato, Italy

[2] Hosp Prato, Azienda USL Toscana Ctr, Sanit Direct, Prato, Italy

[3] Hosp Prato, Azienda USL Toscana Ctr, Div Internal Med 2, Prato, Italy

[4] Hosp Prato, Azienda USL Toscana Ctr, Div Infect Dis, Prato, Italy

[5] Santa Maria Nuova Hosp, Azienda USL Toscana Ctr, Dept Med Specialties, Div Internal Med, Florence, Italy

[6] Hosp Pistoia, Azienda USL Toscana Ctr, Div Infect Dis, Pistoia, Italy

[7] AO SS Antonio & Biagio & C Arrigo, Rheumatol Unit, Alessandria, Italy

[8] Osped Riuniti Marche Nord, Azienda Osped, Div Internal Med, Fano Pesaro, Italy

[9] Natl Inst Infect Dis, Clin Epidemiol Unit, Rome, Italy

[10] IRCCS, Clin Div Infect Dis, Natl Inst Infect Dis, Rome, Italy

[11] Univ Sassari, Clin Epidemiol & Med Stat Unit, Dept Med Surg & Expt Sci, Sassari, Italy

[12] IRCCS, Translat Res Unit, Dept Epidemiol & Preclin Res, L Spallanzani Natl Inst Infect Dis INMI, Rome, Italy

来源：

JOURNAL OF INFECTION | 2020年 / 81卷 / 04期

关键词：

D O I：

10.1016/j.jinf.2020.06.052

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：673 / 677

页数：5

共 9 条

[1] Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, Japan
Adachi, Takuya
Chong, Ja-Mun
Nakajima, Noriko
Sano, Masahiro
Yamazaki, Jun
Miyamoto, Ippei
Nishioka, Haruka
Akita, Hidetaka
Sato, Yuko
Kataoka, Michiyo
Katano, Harutaka
Tobiume, Minoru
Sekizuka, Tsuyoshi
Itokawa, Kentaro
Kuroda, Makoto
Suzuki, Tadaki
[J]. EMERGING INFECTIOUS DISEASES, 2020, 26 (09) : 2157 - 2161
[2] [Anonymous], 2020, EMBO MOL MED, DOI DOI 10.15252/emmm.202012697
[3] Cantini F, 2020, J INFECTION, V81, P318, DOI [10.1016/j.jinf.2020.04.017, 10.1016/j.jinf.2020.06.052]
[4] Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease
Goletti, Delia
Lee, Meng-Rui
Wang, Jann-Yuan
Walter, Nicholas
Ottenhoff, Tom H. M.
[J]. RESPIROLOGY, 2018, 23 (05) : 455 - 466
[5] Huang CL, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30211-7]
[6] Tocilizumab treatment in COVID-19: A single center experience
Luo, Pan
Liu, Yi
Qiu, Lin
Liu, Xiulan
Liu, Dong
Li, Juan
[J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) : 814 - 818
[7] COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, Justin
Phelan, Anne
Griffin, Ivan
Tucker, Catherine
Oechsle, Olly
Smith, Dan
Richardson, Peter
[J]. LANCET INFECTIOUS DISEASES, 2020, 20 (04) : 400 - 402
[8] Cytokine storm intervention in the early stages of COVID-19 pneumonia
Sun, Xinjuan
Wang, Tianyuan
Cai, Dayong
Hu, Zhiwei
Chen, Jin'an
Liao, Hui
Zhi, Liming
Wei, Hongxia
Zhang, Zhihong
Qiu, Yuying
Wang, Jing
Wang, Aiping
[J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 53 : 38 - 42
[9] Effective treatment of severe COVID-19 patients with tocilizumab
Xu, Xiaoling
Han, Mingfeng
Li, Tiantian
Sun, Wei
Wang, Dongsheng
Fu, Binqing
Zhou, Yonggang
Zheng, Xiaohu
Yang, Yun
Li, Xiuyong
Zhang, Xiaohua
Pan, Aijun
Wei, Haiming
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (20) : 10970 - 10975

← 1 →